Laurence Weiss , Philippe Reix , Helen Mosnier-Pudar , Olivia Ronsin , Jacques Beltrand , Quitterie Reynaud , Laurent Mely , Pierre-Régis Burgel , Nathalie Stremler , Luc Rakotoarisoa , Alfonso Galderisi , Kevin Perge , Nathalie Bendelac , Michel Abely , Laurence Kessler
{"title":"囊性纤维化患者糖耐量异常和糖尿病的筛查策略","authors":"Laurence Weiss , Philippe Reix , Helen Mosnier-Pudar , Olivia Ronsin , Jacques Beltrand , Quitterie Reynaud , Laurent Mely , Pierre-Régis Burgel , Nathalie Stremler , Luc Rakotoarisoa , Alfonso Galderisi , Kevin Perge , Nathalie Bendelac , Michel Abely , Laurence Kessler","doi":"10.1016/j.diabet.2023.101444","DOIUrl":null,"url":null,"abstract":"<div><p>The increase in life expectancy of patients with cystic fibrosis has come with new comorbidities, particularly diabetes. The gradual development of glucose tolerance abnormalities means that 30 to 40% of adults will be diabetic. Cystic fibrosis–related diabetes is a major challenge in the care of these patients because it is a morbidity and mortality factor at all stages of the disease. Early glucose tolerance abnormalities observed from childhood, before the stage of diabetes, are also associated with a poor pulmonary and nutritional outcome. The long asymptomatic period justifies systematic screening with an annual oral glucose tolerance test from the age of 10 years. However, this strategy does not take into account the new clinical profiles of patients with cystic fibrosis, recent pathophysiological knowledge of glucose tolerance abnormalities, and the emergence of new diagnostic tools in diabetology. In this paper, we summarise the challenges of screening in the current context of new patient profiles – patients who are pregnant, have transplants, or are being treated with fibrosis conductance transmembrane regulator modulators – and put forward an inventory of the various screening methods for cystic fibrosis–related diabetes, including their applications, limitations and practical implications.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 3","pages":"Article 101444"},"PeriodicalIF":4.6000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis\",\"authors\":\"Laurence Weiss , Philippe Reix , Helen Mosnier-Pudar , Olivia Ronsin , Jacques Beltrand , Quitterie Reynaud , Laurent Mely , Pierre-Régis Burgel , Nathalie Stremler , Luc Rakotoarisoa , Alfonso Galderisi , Kevin Perge , Nathalie Bendelac , Michel Abely , Laurence Kessler\",\"doi\":\"10.1016/j.diabet.2023.101444\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The increase in life expectancy of patients with cystic fibrosis has come with new comorbidities, particularly diabetes. The gradual development of glucose tolerance abnormalities means that 30 to 40% of adults will be diabetic. Cystic fibrosis–related diabetes is a major challenge in the care of these patients because it is a morbidity and mortality factor at all stages of the disease. Early glucose tolerance abnormalities observed from childhood, before the stage of diabetes, are also associated with a poor pulmonary and nutritional outcome. The long asymptomatic period justifies systematic screening with an annual oral glucose tolerance test from the age of 10 years. However, this strategy does not take into account the new clinical profiles of patients with cystic fibrosis, recent pathophysiological knowledge of glucose tolerance abnormalities, and the emergence of new diagnostic tools in diabetology. In this paper, we summarise the challenges of screening in the current context of new patient profiles – patients who are pregnant, have transplants, or are being treated with fibrosis conductance transmembrane regulator modulators – and put forward an inventory of the various screening methods for cystic fibrosis–related diabetes, including their applications, limitations and practical implications.</p></div>\",\"PeriodicalId\":11334,\"journal\":{\"name\":\"Diabetes & metabolism\",\"volume\":\"49 3\",\"pages\":\"Article 101444\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes & metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1262363623000265\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1262363623000265","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis
The increase in life expectancy of patients with cystic fibrosis has come with new comorbidities, particularly diabetes. The gradual development of glucose tolerance abnormalities means that 30 to 40% of adults will be diabetic. Cystic fibrosis–related diabetes is a major challenge in the care of these patients because it is a morbidity and mortality factor at all stages of the disease. Early glucose tolerance abnormalities observed from childhood, before the stage of diabetes, are also associated with a poor pulmonary and nutritional outcome. The long asymptomatic period justifies systematic screening with an annual oral glucose tolerance test from the age of 10 years. However, this strategy does not take into account the new clinical profiles of patients with cystic fibrosis, recent pathophysiological knowledge of glucose tolerance abnormalities, and the emergence of new diagnostic tools in diabetology. In this paper, we summarise the challenges of screening in the current context of new patient profiles – patients who are pregnant, have transplants, or are being treated with fibrosis conductance transmembrane regulator modulators – and put forward an inventory of the various screening methods for cystic fibrosis–related diabetes, including their applications, limitations and practical implications.
期刊介绍:
A high quality scientific journal with an international readership
Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing.
Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.